The insider sales are small in dollar terms but notable for timing — both C-suite officers sold the same day, two days after a material manufacturing agreement filing. Monitor for any additional insider sales in the next 30 days; if selling continues or accelerates, it would signal reduced confidence in the avexitide commercial timeline. The $30M upfront payment to Polypeptide is a cash outflow that may pressure near-term cash runway, but the manufacturing agreements themselves are a positive step toward commercial readiness.
Price Chart
Executive Summary
Two C-suite insiders at Amylyx (CFO and CMO) sold a combined ~$103K in open-market sales on September 10, 2026, just two days after the company disclosed material manufacturing agreements for avexitide drug substance supply. The sales follow a $30M upfront capacity-reservation payment to Polypeptide and long-term supply commitments with Bachem and Polypeptide starting in 2028. While the dollar amount is trivial relative to the $4.0B market cap (~0.003%), the timing — immediately after a material agreement filing — raises questions about insider sentiment on the avexitide commercial ramp timeline and cash burn implications of the $30M upfront payment.
Key Financial Metrics
Key Facts
- CFO James Frates sold 10,810 shares total (~$350K) on Sept 10, 2026
- CMO Camille Bedrosian sold 10,028 shares total (~$325K) on Sept 10, 2026
- Sales occurred 2 days after 8-K filing disclosing $30M upfront payment to Polypeptide for avexitide manufacturing capacity
- Total open-market sales of ~$103K represent ~0.003% of $4.0B market cap — trivial by proportionality
- Manufacturing agreements secure long-term supply of avexitide drug substance starting 2028, pending regulatory approval
Financial Impact
Insider sales of ~$103K open-market value; $30M upfront capacity reservation payment to Polypeptide disclosed in 8-K
Risk Factors
- Insider sales immediately after material agreement filing could indicate concerns about avexitide approval/commercialization timeline
- $30M upfront payment to Polypeptide reduces cash reserves without guaranteed regulatory approval
- Manufacturing agreements with minimum purchase commitments starting 2028 create fixed cost obligations before product revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-AMLX-1789448859479 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 144 | $28.04 | awaiting T+20 | — | $27.09 (−3.39%) |
Sep 14, 2026 6w ago | Insider Cluster | $33.15 $26.85 | ▼ −19.00% | ▼ −21.73% | $27.09 (−18.28%) |
Sep 11, 2026 6w ago | 144 | $33.64 $27.48 | ▼ −18.31% | ▼ −20.57% | $27.09 (−19.47%) |
Aug 18, 2026 9w ago | 8-K | $35.11 $33.05 | ▼ −5.87% | ▼ −4.88% | $27.09 (−22.84%) |
Aug 15, 2026 10w ago | Institutional Cluster | $21.43 $33.15 | ▲ +54.69% | ▲ +56.67% | $27.09 (+26.41%) |
Aug 6, 2026 11w ago | 8-K | $24.19 $33.96 | ▲ +40.39% | ▲ +39.79% | $27.09 (+11.99%) |
Jun 11, 2026 19w ago | Institutional Cluster | $13.91 $18.38 | ▲ +32.14% | ▲ +30.24% | $27.09 (+94.75%) |
Apr 23, 2026 26w ago | DEFA14A | $17.32 $13.61 | ▼ −21.42% | ▼ −26.05% | $27.09 (+56.41%) |
Mar 2, 2026 34w ago | Insider Cluster | $15.30 $12.76 | ▼ −16.60% | ▼ −8.66% | $27.09 (+77.06%) |
Feb 23, 2026 35w ago | Insider Cluster | $13.90 $13.53 | ▲ +2.66% | ▼ −1.28% | $27.09 (−94.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers